Patents by Inventor I. Robert Silverman

I. Robert Silverman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS
    Publication number: 20250346604
    Abstract: Disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier or diluent and a compound of Formula I: or a pharmaceutically acceptable salt thereof. The variables are defined herein. Also disclosed is a method of treating cancer with the pharmaceutical formulation.
    Type: Application
    Filed: April 24, 2025
    Publication date: November 13, 2025
    Inventors: Erik T. Goka, I. Robert Silverman, Alan Bruce Cooper
  • TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS
    Publication number: 20250235453
    Abstract: Disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier or diluent and a compound of Formula I: or a pharmaceutically acceptable salt thereof. The variables are defined herein. Also disclosed is a method of treating cancer with the pharmaceutical formulation.
    Type: Application
    Filed: October 25, 2022
    Publication date: July 24, 2025
    Inventors: Erik T. Goka, I. Robert Silverman, Alan Bruce Cooper
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20250025467
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: October 3, 2024
    Publication date: January 23, 2025
    Inventors: I. Robert SILVERMAN, Julie F. LIU, Adam J. MORGAN, Bhaumik PANDYA, Scott L. HARBESON
  • Deuterated JAK inhibitor and uses thereof
    Patent number: 11919907
    Abstract: Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: or a pharmaceutically acceptable salt thereof. This invention also provides pharmaceutical compositions comprising a compound of Formula (I), optionally including additional therapeutic agents, and use in methods of treatment for hair loss disorders.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: March 5, 2024
    Assignee: Sun Pharmaceutical Industries, Inc.
    Inventors: I. Robert Silverman, Changhua Liu
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20230355629
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: December 9, 2022
    Publication date: November 9, 2023
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • NOVEL DEUTERATED JAK INHIBITOR AND USES THEREOF
    Publication number: 20210387991
    Abstract: Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: or a pharmaceutically acceptable salt thereof. This invention also provides pharmaceutical compositions comprising a compound of Formula (I), optionally including additional therapeutic agents, and use in methods of treatment for hair loss disorders.
    Type: Application
    Filed: May 21, 2021
    Publication date: December 16, 2021
    Inventors: I. Robert Silverman, Changhua Liu
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20210330674
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: December 10, 2020
    Publication date: October 28, 2021
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • DEUTERATED ANALOGS OF D-BETA-HYDROXYBUTYRIC ACID AND USES THEREOF
    Publication number: 20210008018
    Abstract: This disclosure relates to deuterated D-?-hydroxybutyric acid (DBHB) of Formula I: wherein each of the variables are defined herein, and pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 14, 2021
    Inventors: Roger D. Tung, I. Robert Silverman, Naeem Yusuff
  • Morphinan compounds
    Patent number: 10813926
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: October 27, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Deuterated CFTR modulators
    Patent number: 10738036
    Abstract: This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 11, 2020
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventors: I. Robert Silverman, Roger D. Tung
  • MORPHINAN COMPOUNDS
    Publication number: 20200022975
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: July 26, 2019
    Publication date: January 23, 2020
    Applicant: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20190308976
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: March 11, 2019
    Publication date: October 10, 2019
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • DEUTERATED CFTR MODULATORS
    Publication number: 20190284175
    Abstract: This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.
    Type: Application
    Filed: October 22, 2018
    Publication date: September 19, 2019
    Inventors: I. Robert SILVERMAN, Roger D. TUNG
  • Morphinan compounds
    Patent number: 10406155
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: September 10, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20190100484
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: August 6, 2018
    Publication date: April 4, 2019
    Inventors: Roger D. Tung, Adam J. Morgan, I. Robert Silverman
  • MORPHINAN COMPOUNDS
    Publication number: 20190038618
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: July 16, 2018
    Publication date: February 7, 2019
    Inventors: Philip B. Graham, I. Robert Silverman
  • Deuterated CFTR modulators
    Patent number: 10196384
    Abstract: This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: February 5, 2019
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventors: I. Robert Silverman, Roger D. Tung
  • Morphinan compounds
    Patent number: 10022370
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 17, 2018
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • DEUTERATED VX-661
    Publication number: 20180111920
    Abstract: This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.
    Type: Application
    Filed: March 30, 2016
    Publication date: April 26, 2018
    Inventors: I. Robert SILVERMAN, Roger D. TUNG
  • DEUTERATED TIC10
    Publication number: 20180016277
    Abstract: This invention relates to novel imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions alone or in combination with other therapeutics in the treatment of diseases and conditions that are beneficially treated by administering an inducer of the gene encoding tumor necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL) superfamily member 10.
    Type: Application
    Filed: January 27, 2016
    Publication date: January 18, 2018
    Inventor: I. Robert Silverman